WILMINGTON, Mass. - Charles River Laboratories International, Inc. (NYSE: CRL) has announced a distribution agreement with Pluristyx Inc., enhancing its research tools for therapeutic development. The deal grants Charles River access to Pluristyx's embryonic stem (ES) cells and induced pluripotent stem cells (iPSCs), which are essential for studying disease and developing treatments.
Pluristyx, a provider of cell therapy development tools and services, produces pluripotent cell lines under full donor consent, with its ES cell lines approved by the U.S. National Institutes of Health (NIH) for NIH-funded research. The company's iPSC panCELLa platform features FailSafe safety-switch technology aimed at creating safer cell therapies.
Charles River will distribute a wide array of Pluristyx's ES and iPSC lines for research purposes, and exclusively offer specific stem cell lines developed under Good Tissue Practice to support clinical pathways. The addition of these cell lines complements Charles River's portfolio of human cellular materials, which is utilized in areas such as stem cell biology, disease modeling, and drug discovery.
The collaboration is part of Charles River's commitment to reducing the use of in vivo research models and advancing human-derived in vitro models for therapeutic research. The alliance will provide Charles River clients with advanced tools for cell-based assays in drug discovery.
Birgit Girshick, Executive Vice President and Chief Operating Officer at Charles River, expressed enthusiasm for integrating Pluristyx's offerings into their portfolio, emphasizing the potential to develop safe and effective therapies worldwide. Benjamin Fryer, PhD, Chief Executive Officer of Pluristyx, also highlighted the partnership's role in advancing the development of next-generation therapies.
The financial terms of the agreement were not disclosed. This strategic move is expected to strengthen Charles River's position in the market and support the scientific community's progress in creating innovative treatments. The information is based on a press release statement from Charles River Laboratories International, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.